Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.

Breast Cancer Res Treat 2018 Apr 16;168(2):523-530. Epub 2017 Dec 16.

Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.

Purpose: We assessed bone mineral density (BMD) change with aromatase inhibitor (AI) treatment in a contemporary cohort of women with breast cancer treated in Kaiser Permanente Northern California.

Methods: Percent and estimated annual percent changes in BMD at the total hip and lumbar spine were examined in 676 women receiving AI therapy who had two serial BMD reports available (at least 1 year apart) before and after AI initiation (N = 317) or during continued AI therapy (N = 359). BMD changes were examined at the total hip and lumbar spine and compared by age and clinical subgroups.

Results: Women experienced BMD declines after AI initiation or continued therapy, with median annual percent change - 1.2% (interquartile range, IQR - 2.4 to - 0.1%) at the hip and - 1.0% (IQR - 2.3 to 0.1%) at the spine after AI initiation, and - 1.1% (IQR - 2.4 to 0.1%) at the hip and - 0.9% (IQR - 2.4 to 0.5%) at the spine during continued therapy. Higher levels of bone loss were observed among younger (< 55 years) compared with older (≥ 75 years) women at the hip (- 1.6% vs. - 0.8%) and at the spine (- 1.5% vs. - 0.5%) after AI initiation, and at the hip (- 1.4% vs. - 1.2%) and at the spine (- 2.4% vs. - 0.001%) during continued therapy.

Conclusions: Small but consistent declines in total hip and lumbar spine BMD were present in breast cancer patients following AI therapy initiation or continued AI therapy. Although the overall rates of osteoporosis were low, greater estimated levels of annual bone loss were evident among women < 55 years.

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4626-5
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4626-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534130PMC
April 2018
8 Reads

Publication Analysis

Top Keywords

iqr - 24
12
continued therapy
12
aromatase inhibitor
8
breast cancer
8
annual percent
8
hip lumbar
8
women breast
8
total hip
8
lumbar spine
8
mineral density
8
bone mineral
8
bmd
5
therapy
5
hip - 09%
4
therapy n = 359
4
n = 317 continued
4
initiation n = 317
4
bmd changes
4
01% hip
4
compared age
4

References

(Supplied by CrossRef)

HJ Burstein et al.
J Clin Oncol 2010

M Dowsett et al.
J Clin Oncol 2010

P Hadji et al.
Crit Rev Oncol Hematol 2009

AJ Chien et al.
J Clin Oncol 2006

M Liu et al.
Mol Endocrinol 2014

PE Goss et al.
N Engl J Med 2016

R Bartsch et al.
Memo 2016

ML Kwan et al.
PLoS ONE 2014

S Yao et al.
Breast Cancer Res Treat 2017

JC Lo et al.
Osteoporos Int 2016

S Bonnick et al.
2010

Similar Publications